PMA device
MiSight 1 Day (omafilcon A) Soft (Hydrophilic) Contact Lenses for Daily Wear
CooperVision, Inc. · Daily Wear Soft Contact Lens To Reduce The Progression Of Myopia (QIT, Class III) · First FDA decision Nov 15, 2019, newest Dec 17, 2025Nearsightedness and refractive error
Last checked: Nov 20, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
11
PMA pathway
Device trials
18
Naming "MiSight 1 Day"
MAUDE reports
16
Brand "MiSight 1 Day", since 2015
PubMed studies
25
Mentioning "MiSight 1 Day"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing MiSight 1 Day (omafilcon A) Soft (Hydrophilic) Contact Lenses for Daily Wear
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 6 of 11 decisions filed under this name.
P180035-S032 · Decided Dec 17, 2025 · 75 days after receipt · Normal 180 Day Track No User Fee
Device type: Daily wear soft contact lens to reduce the progression of myopia (QIT) · Ophthalmology
P180035-S031 · Decided Oct 28, 2025 · 62 days after receipt · Normal 180 Day Track No User Fee
Device type: Daily wear soft contact lens to reduce the progression of myopia (QIT) · Ophthalmology
P180035-S020 · Decided Jul 10, 2024 · 85 days after receipt · Normal 180 Day Track No User Fee
Device type: Daily wear soft contact lens to reduce the progression of myopia (QIT) · Ophthalmology
3 more FDA decisions with a free account
Older decisions: P180035-S012, P180035-S004, P180035-S003, P180035-S001, P180035
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
No Medicare coverage document has a title matching this device or device type. Many devices are paid under existing codes without one.
Clinical trials
Device studies on ClinicalTrials.gov that name "MiSight 1 Day", any status and sponsor, newest update first.
Ohio State UniversityAcademic, hospital or other
NCT06450132 · 75 participants · Start Aug 1, 2024 · Primary completion Sep 4, 2026
Device: MiSight 1-day disposable contact lenses · For: Myopia
Sites: Columbus, Ohio
- Using Contact Lenses and Spectacle Lenses as Myopia Interventions.Not yet recruiting
CooperVision International Limited (CVIL)Not on our public-company list
NCT07845721 · 58 participants (planned) · Start Dec 2026 · Primary completion Feb 2028
Device: Test Spectacle Lens & Contact Lens; Control Spectacle Lens & Contact Lens · For: Myopia
Sites: Waterloo, Canada; Birmingham, United Kingdom
- The Effect of Myopia-Control Contact Lenses in New Zealand Chinese ChildrenActive, not recruiting
Aston UniversityAcademic, hospital or other
NCT07535749 · 66 participants (planned) · Start Mar 21, 2026 · Primary completion Apr 30, 2027
Device: MiSight Contact Lenses (CooperVision); Albiliti 1-Day (Johnson and Johnson, VisionCare) · For: Myopia Progression
Sites: Auckland, New Zealand
15 more trials with a free account
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "MiSight 1 Day", and for the whole product code for context.
This brand
16 reports: 0 malfunction, 16 injury, 0 death
Whole product code QIT
16 reports: 0 malfunction, 16 injury, 0 death
Newest reports for this brand
COOPERVISION MANUFACTURING LTD
3003981983-2025-00006 · Received Dec 5, 2025
Device type: Daily Wear Soft Contact Lens To Reduce The Progression Of Myopia (QIT)
Device problem as coded: Insufficient Device Problem Information
Patient problem as coded: Corneal Ulcer; Visual Impairment; Eye Infections
COOPERVISION MANUFACTURING, LTD
3003981983-2025-00005 · Received Oct 1, 2025
Device type: Daily Wear Soft Contact Lens To Reduce The Progression Of Myopia (QIT)
Device problem as coded: Insufficient Device Problem Information
Patient problem as coded: Corneal Abrasion; Corneal Scar; Corneal Ulcer; Corneal Infiltrates; Eye Infections; Eye Pain
COOPERVISION MANUFACTURING LTD
3003981983-2025-00004 · Received Jul 3, 2025
Device type: Daily Wear Soft Contact Lens To Reduce The Progression Of Myopia (QIT)
Device problem as coded: Insufficient Device Problem Information
Patient problem as coded: Corneal Ulcer
2 more reports with a free account
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "MiSight 1 Day"[tiab]. The summary above synthesizes these.
- Clinical Efficacy of MiSight 1 day Soft Contact Lenses in Korean Myopic Children.
Kim HK, Jo MH, Jo YJ, et al. · Eye Contact Lens · 2024
- A 3-year Randomized Clinical Trial of MiSight Lenses for Myopia Control.
Chamberlain P, Peixoto-de-Matos SC, Logan NS, et al. · Optom Vis Sci · 2019Multicenter Study, Randomized Controlled Trial
- Low-Concentration Atropine Monotherapy vs. Combined with MiSight 1 Day Contact Lenses for Myopia Management.
Erdinest N, London N, Lavy I, et al. · Vision (Basel) · 2022
- Axial length targets for myopia control.
Chamberlain P, Lazon de la Jara P, Arumugam B, et al. · Ophthalmic Physiol Opt · 2021Comparative Study, Randomized Controlled Trial
- Real-world effectiveness of MiSight 1 Day contact lenses in Taiwanese children: a multicenter retrospective study.
Huang YT, Wang IM, Huang YH, et al. · Front Med (Lausanne) · 2026
- Six years of wearer experience in children participating in a myopia control study of MiSight® 1 day.
Lumb E, Sulley A, Logan NS, et al. · Cont Lens Anterior Eye · 2023Randomized Controlled Trial
- Long-term Effect of Dual-focus Contact Lenses on Myopia Progression in Children: A 6-year Multicenter Clinical Trial.
Chamberlain P, Bradley A, Arumugam B, et al. · Optom Vis Sci · 2022Multicenter Study, Research Support, Non-U.S. Gov't
- Myopia Control Dose Delivered to Treated Eyes by a Dual-focus Myopia-control Contact Lens.
Ramasubramanian V, Logan NS, Jones S, et al. · Optom Vis Sci · 2023
- Optical characterisation and vision quality assessment of two myopia control contact lenses.
Richards J, Jaskulski M, Woods J, et al. · Ophthalmic Physiol Opt · 2025Randomized Controlled Trial
- Six-year cumulative treatment effect and treatment efficacy of a dual focus myopia control contact lens.
Chamberlain P, Hammond DS, Arumugam B, et al. · Ophthalmic Physiol Opt · 2024
- Treatment of Rapid Progression of Myopia: Case Series and Literature Review.
Erdinest N, London N, Levinger N, et al. · Case Rep Ophthalmol · 2021Case Reports
- Establishing non-inferiority margins in myopia management contact lens trials with an active control.
Bakaraju RC, Tilia D · BMJ Open Ophthalmol · 2025
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.